NEW YORK, NY — (Marketwire) — 03/26/13 — Nuvilex, Inc. (OTCQB: NVLX) is a small biotechnology company out of Silver Spring, Maryland, but its future might be anything but small. As the company diligently prepares for its Phase III pancreatic cancer trials, the almost $30-million the company has invested in its unique and proprietary living cell encapsulation or “Cell-in-a-Box” technology could be money well spent given the return in annual sales that cancer drugs bring in the marketplace.
Nuvilex has about $25-million invested in two independent Phase II clinical trials in patients with advanced, inoperable pancreatic cancer using the combination of the widely used anti-cancer drug, ifosfamide, together with encapsulated cells capable of converting the ifosfamide into its “cancer-killing” form and in preclinical studies of other applications for the technology. In addition, the company has put almost another $2-million into furthering the development of the “Cell-in-a-Box” technology itself.
This is a pretty hefty price tag for such a small biotech, but with the results the company has seen to date in its two clinical trials, the future looks very bright. In those trials, the results show that Nuvilex-s treatment outperforms the current standard, Eli Lilly-s Gemzar.
Why is this significant to Nuvilex? It-s all about the math and right now Gemzar — the standard single drug for pancreatic cancer patients — equals about $1.4-billion annually to Eli Lilly. That-s billion with a B. Cancer drugs are big business, and those drugs are even bigger business when they work, and when they extend lives, and so far, Nuvilex-s cell encapsulation technology has shown it does work and it does extend lives.
Before we look at the results that are better than the current standard, let-s look at how the technology works and why, quite frankly, it-s better than adding another drug to a cancer patient-s daily routine.
Continue reading the rest of this article at
About Stock House Group
Stock House Group is a full service Investment Relations firm specializing in Awareness, Research, and Content Development. The firm offers a platform to CEOs to develop their story through the press, Research Reports, and CEO Interviews. At the same time, we-re building a library of Research to assist Investors in their due diligence on micro, small and large cap stocks.
Contact:
Stock House Group
646-397-4020